Zacks: Analysts Expect VERONA PHARMA P/S (NASDAQ:VRNA) to Post -$0.89 Earnings Per Share

Wall Street analysts forecast that VERONA PHARMA P/S (NASDAQ:VRNA) will post earnings per share (EPS) of ($0.89) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for VERONA PHARMA P/S’s earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($1.05). VERONA PHARMA P/S posted earnings of ($0.23) per share during the same quarter last year, which would indicate a negative year over year growth rate of 287%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.

Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover VERONA PHARMA P/S.

VERONA PHARMA P/S (NASDAQ:VRNA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.27).

A number of brokerages recently issued reports on VRNA. Zacks Investment Research upgraded shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating and set a $5.50 target price for the company in a research report on Tuesday, July 16th. Wedbush restated an “outperform” rating and issued a $58.00 price target on shares of VERONA PHARMA P/S in a research report on Monday, July 29th. Finally, ValuEngine raised shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

Shares of NASDAQ VRNA traded up $0.30 during midday trading on Thursday, reaching $4.60. 5,600 shares of the company traded hands, compared to its average volume of 6,861. The firm has a market cap of $59.25 million, a PE ratio of -2.28 and a beta of -1.00. The stock’s 50-day simple moving average is $4.34 and its 200-day simple moving average is $5.52. VERONA PHARMA P/S has a 12 month low of $3.65 and a 12 month high of $14.50.

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.

Featured Article: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on VERONA PHARMA P/S (VRNA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for VERONA PHARMA P/S (NASDAQ:VRNA)

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with's FREE daily email newsletter.